Atorka engages Landsbanki to investigate the sale of three healthcare companies

Atorka has decided to work toward the sale of three companies in its portfolio. The companies in question, all of which operate in the healthcare sector in Iceland and the Baltics, are Parlogis hf, Icepharma hf, and UAB Ilsanta. Atorka has engaged Landsbanki Corporate Finance to carry out the sale process over the next several weeks. 

This decision is part of Atorka's revised strategy, according to which the company now emphasises larger investments in companies with the potential for substantial internal and external growth on a global level. Atorka's largest investments at the present time are Promens, Jardboranir, and Interbulk.

In recent years, Atorka has made significant changes in Parlogis, Icepharma, and Ilsanta, with excellent results. Operations at these three companies have been good in recent quarters, and the outlook for the future is excellent. 

Parlogis is a specialised logistics service provider that concentrates on broad-based logistics for the healthcare sector, with a focus on some 30 market and production companies. 
Icepharma hf is an Icelandic market leader in the pharmaceuticals and healthcare sector. At the end of 2005, Austurbakki and Ísmed merged with Icepharma. The company has a strong position in all segments of its operations, which include its pharmaceuticals division, healthcare division, consumer products division, and athletics division. 
 
Ilsanta is a leading sales and distribution company that handles medical equipment and nursing products for healthcare centres in the Baltic countries. It maintains business locations in Vilnius, Riga, and Tallinn.

For further information please contact Benedikt Olgeirsson Managing Director at Atorka, tel. +354 840 6210